Advertisement

Breast Disease pp 103-127 | Cite as

Adjuvant Systemic Therapy: Endocrine Therapy

  • Ibrahim Yildiz
  • Pinar Saip
Chapter

Abstract

Estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive breast cancers are the most common types of breast cancer, accounting for 75% of all breast cancers. Adjuvant endocrine therapy is a pivotal component of treatment for women with hormone receptor-positive early-stage breast cancer; it delays local and distant relapse and prolongs survival. Patients with ER- and/or PR-positive invasive breast cancers should be considered for adjuvant endocrine therapy regardless of age, lymph node status, or adjuvant chemotherapy use. Features indicative of uncertain endocrine responsiveness include low levels of hormone receptor immunoreactivity, PR negativity, poor differentiation (grade 3), high Ki-67 index, human epidermal growth factor receptor 2 overexpression, and high gene recurrence score. Adjuvant hormonal manipulation is achieved by blocking the ER in breast tumor tissues with tamoxifen in premenopausal and postmenopausal women, lowering systemic estrogen levels with luteinizing hormone-releasing hormone agonists in premenopausal women, or blocking estrogen biosynthesis in nonovarian tissues with aromatase inhibitors in postmenopausal women.

Keywords

Breast cancer Endocrine therapy Adjuvant therapy 

References

  1. 1.
    Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001;7:4338s–42s; discussion 4411s–4412s.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Kumar R, Thompson EB. The structure of the nuclear hormone receptors. Steroids. 1999;64:310–9.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926–35.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884–8.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Goldhirsch A, Coates AS, Gelber RD, et al. First–select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006;17:1772–6.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–9.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Filipits M, Nielsen TO, Rudas M, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20:1298–305.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560–9.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005–14.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. Monographs. 1992;11:105–16.Google Scholar
  19. 19.
    Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.PubMedCrossRefGoogle Scholar
  21. 21.
    De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376:911–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Knauff EA, Eijkemans MJ, Lambalk CB, et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009;94:786–92.PubMedCrossRefGoogle Scholar
  23. 23.
    Torino F, Barnabei A, De Vecchis L, et al. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. Endocr Relat Cancer. 2012;19:R21–33.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Soules MR, Sherman S, Parrott E, et al. Stages of reproductive aging workshop (STRAW). J Womens Health Gend Based Med. 2001;10:843–8.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    De Vos FY, van Laarhoven HW, Laven JS, et al. Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Crit Rev Oncol Hematol. 2012;84:252–60.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009;27:3192–7.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009;63:280–91.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–29.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11:422–34.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–31.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Najafi S, Djavid GE, Mehrdad N, et al. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. Menopause. 2011;18:208–12.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113:315–20.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.CrossRefGoogle Scholar
  34. 34.
    Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Sutherland RL, Green MD, Hall RE, et al. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol. 1983;19:615–21.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Hug V, Hortobagyi GN, Drewinko B, Finders M. Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol. 1985;3:1672–7.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:2055–63.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Lonning PE. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opin Investig Drugs. 2010;19(Suppl 1):S19–30.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–42.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer. 1996;74:297–9.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Petrelli F, Coinu A, Cabiddu M, et al. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res Treat. 2013;140:233–40.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Piccart MJ, Di Leo A, Hamilton A. HER2: a ‘predictive factor’ ready to use in the daily management of breast cancer patients? Eur J Cancer. 2000;36:1755–61.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004;10:5670–6.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000;18:3471–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol. 2000;27:46–52; discussion 92–100.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059–65.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104:441–51.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104:452–60.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348:1189–96.CrossRefGoogle Scholar
  51. 51.
    Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast. 2009;18(Suppl 3):S122–30.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–23.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Aydiner A, Kilic L, Yildiz I, et al. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients. Med Oncol. 2013;30:354.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–18.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122–37.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Davidson NE, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005;23:5973–82.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Ejlertsen B, Mouridsen HT, Jensen MB, et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol. 2006;24:4956–62.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer. 2003;39:1711–7.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Schmid P, Untch M, Wallwiener D, et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res. 2002;22:2325–32.PubMedPubMedCentralGoogle Scholar
  60. 60.
    von Minckwitz G, Graf E, Geberth M, et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer. 2006;42:1780–8.CrossRefGoogle Scholar
  61. 61.
    Castiglione-Gertsch M, O’Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003;95:1833–46.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy’s Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet. 1993;341:1293–8.Google Scholar
  63. 63.
    Schmid P, Untch M, Kosse V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol. 2007;25:2509–15.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it. J Clin Oncol. 2000;18:2718–27.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol. 2006;17:1221–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20:4621–7.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006;42:895–904.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27–36.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–76.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12:1101–8.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377:321–31.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99:1845–53.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26:1965–71.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019;37(5):423–38.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–70.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007;25:2664–70.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–36.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–82.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135–41.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–9.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Duffy S, Jackson TL, Lansdown M, et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod. 2006;21:545–53.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22:4261–71.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051–7.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer. 2001;85:317–24.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Buzdar AU, Guastalla JP, Nabholtz JM, et al. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer. 2006;107:472–80.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29:1117–24.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25:5715–22.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009;20:1489–98.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Viale G, Regan MM, Dell’Orto P, et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol. 2011;22:2201–7.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Aydiner A, Tas F. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer. Trials. 2008;9:47.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–47.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17(Suppl 7):vii10–4.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7:991–6.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–62.PubMedCrossRefGoogle Scholar
  101. 101.
    Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012;30:718–21.PubMedCrossRefGoogle Scholar
  103. 103.
    Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35.PubMedCrossRefGoogle Scholar
  104. 104.
    Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23:6931–40.PubMedCrossRefGoogle Scholar
  105. 105.
    Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–19.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017;18:1502–11.PubMedCrossRefGoogle Scholar
  107. 107.
    Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst. 2018;110:40–8.CrossRefGoogle Scholar
  108. 108.
    Goldvaser H, AlGorashi I, Ribnikar D, et al. Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: a systematic review and meta-analysis. Cancer Treat Rev. 2017;60:53–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Colleoni M, Luo W, Karlsson P, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:127–38.PubMedCrossRefGoogle Scholar
  110. 110.
    Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656–64.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167–70.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Tung N. What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer? J Clin Oncol. 2013;31:1391–7.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751–7.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26:1671–6.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29:2342–9.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial. J Clin Oncol. 2013;31:1398–404.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–309.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    O’Shaughnessy J. A decade of letrozole: FACE. Breast Cancer Res Treat. 2007;105(Suppl 1):67–74.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30:936–42.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Aydiner A. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast. 2013;22:121–9.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ibrahim Yildiz
    • 1
  • Pinar Saip
    • 2
  1. 1.Department of Medical Oncology, Medical FacultyAcibadem Mehmet Ali Aydinlar University HospitalIstanbulTurkey
  2. 2.Department of Medical Oncology, Institute of OncologyIstanbul UniversityIstanbulTurkey

Personalised recommendations